nach oben

Erschienen in:

03.12.2015 | Fortbildung

Schlaganfall

Sekundärprophylaxe mit oralen Antikoagulanzien

verfasst von: Dr. med. Jan C. Purrucker, Prof. Dr. med. Peter A. Ringleb, PD Dr. med. Timolaos Rizos

Erschienen in: DNP – Die Neurologie & Psychiatrie | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Eine orale Antikoagulation ist bei Patienten mit nicht valvulärem Vorhofflimmern nach Schlaganfall oder transitorischer ischämischer Attacke indiziert. Für diese Patienten werden die neuen, nicht VKA-oralen Antikoagulanzien auch in der kürzlich aktualisierten S3-Leitlinie „Sekundärprophylaxe ischämischer Schlaganfall und transitorische ischämische Attacke“ empfohlen.

Heuschmann PU, Busse O, Wagner M, Endres M, Villringer A, Röther J, Kolominsky-Rabas PL, Berger K (2010) Schlaganfallhäufigkeit und Versorgung von Schlaganfallpatienten in Deutschland (Frequency and Care of Stroke in Germany). Akt Neurol 37 (07):333–340. doi:10.1055/s-0030-1248611CrossRef

Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, Fang MC, Fisher M, Furie KL, Heck DV, Johnston SC, Kasner SE, Kittner SJ, Mitchell PH, Rich MW, Richardson D, Schwamm LH, Wilson JA, American Heart Association Stroke Council CoC, Stroke Nursing CoCC, Council on Peripheral Vascular D (2014) Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 45 (7):2160–2236. doi:10.1161/STR.0000000000000024CrossRefPubMed

Endres M, Diener C, Röther J, Behnke M (2015) Sekundärprophylaxe ischämischer Schlaganfall und transitorische ischämische Attacke (Teil 1). AWMF-Registernummer: 030/133.

Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke; a journal of cerebral circulation 22 (8):983–988CrossRefPubMed

Hohnloser SH, Crijns HJGM, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ, Investigators A (2009) Effect of dronedarone on cardiovascular events in atrial fibrillation. The New England journal of medicine 360 (7):668–678. doi:10.1056/NEJMoa0803778CrossRefPubMed

Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener H-C, Joyner CD, Wallentin L, Investigators R-LSCa (2009) Dabigatran versus warfarin in patients with atrial fibrillation. The New England journal of medicine 361 (12):1139–1151. doi:10.1056/NEJMoa0905561CrossRefPubMed

Wolf PA, Abbott RD, Kannel WB (1987) Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 147 (9):1561–1564CrossRefPubMed

Rizos T, Guntner J, Jenetzky E, Marquardt L, Reichardt C, Becker R, Reinhardt R, Hepp T, Kirchhof P, Aleynichenko E, Ringleb P, Hacke W, Veltkamp R (2012) Continuous stroke unit electrocardiographic monitoring versus 24-hour Holter electrocardiography for detection of paroxysmal atrial fibrillation after stroke. Stroke 43 (10):2689–2694. doi:10.1161/STROKEAHA.112.654954CrossRefPubMed

Kallmunzer B, Breuer L, Hering C, Raaz-Schrauder D, Kollmar R, Huttner HB, Schwab S, Kohrmann M (2012) A structured reading algorithm improves telemetric detection of atrial fibrillation after acute ischemic stroke. Stroke 43 (4):994–999. doi:10.1161/STROKEAHA.111.642199CrossRefPubMed

10.

Grond M, Jauss M, Hamann G, Stark E, Veltkamp R, Nabavi D, Horn M, Weimar C, Kohrmann M, Wachter R, Rosin L, Kirchhof P (2013) Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. Stroke 44 (12):3357–3364. doi:10.1161/STROKEAHA.113.001884CrossRefPubMed

11.

Stahrenberg R, Weber-Kruger M, Seegers J, Edelmann F, Lahno R, Haase B, Mende M, Wohlfahrt J, Kermer P, Vollmann D, Hasenfuss G, Groschel K, Wachter R (2010) Enhanced detection of paroxysmal atrial fibrillation by early and prolonged continuous holter monitoring in patients with cerebral ischemia presenting in sinus rhythm. Stroke 41 (12):2884–2888. doi:10.1161/STROKEAHA.110.591958CrossRefPubMed

12.

Seet RC, Friedman PA, Rabinstein AA (2011) Prolonged rhythm monitoring for the detection of occult paroxysmal atrial fibrillation in ischemic stroke of unknown cause. Circulation 124 (4):477–486. doi:10.1161/CIRCULATIONAHA.111.029801CrossRefPubMed

13.

Kishore A, Vail A, Majid A, Dawson J, Lees KR, Tyrrell PJ, Smith CJ (2014) Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke 45 (2):520–526. doi:10.1161/STROKEAHA.113.003433CrossRefPubMed

14.

Liao J, Khalid Z, Scallan C, Morillo C, O’Donnell M (2007) Noninvasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke: a systematic review. Stroke 38 (11):2935–2940. doi:10.1161/STROKEAHA.106.478685CrossRefPubMed

15.

Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, Vaid H, O’Donnell M, Laupacis A, Cote R, Sharma M, Blakely JA, Shuaib A, Hachinski V, Coutts SB, Sahlas DJ, Teal P, Yip S, Spence JD, Buck B, Verreault S, Casaubon LK, Penn A, Selchen D, Jin A, Howse D, Mehdiratta M, Boyle K, Aviv R, Kapral MK, Mamdani M, Investigators E, Coordinators (2014) Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 370 (26):2467–2477. doi:10.1056/NEJMoa1311376CrossRefPubMed

16.

Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, Rymer MM, Thijs V, Rogers T, Beckers F, Lindborg K, Brachmann J, Investigators CA (2014) Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 370 (26):2478–2486.CrossRefPubMed

17.

Sposato LA, Cipriano LE, Saposnik G, Ruiz Vargas E, Riccio PM, Hachinski V (2015) Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol 14 (4):377–387. doi:10.1016/S1474-4422(15)70027-XCrossRefPubMed

18.

Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146 (12):857–867. doi:146/12/857 [pii]CrossRefPubMed

19.

Hart RG, Pearce LA, Aguilar MI (2007) Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med 147 (8):590–592. doi:147/8/590-a [pii]CrossRefPubMed

20.

Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E (2004) The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (3 Suppl):204S–233S. doi:10.1378/chest.126.3_suppl.204SCrossRefPubMed

21.

Rizos T, Jenetzky E, Herweh C, Hug A, Hacke W, Steiner T, Veltkamp R (2010) Point-of-care reversal treatment in phenprocoumon-related intracerebral hemorrhage. Ann Neurol 67 (6):788–793. doi:10.1002/ana.21965PubMed

22.

Franchini M, Lippi G (2010) Prothrombin complex concentrates: an update. Blood Transfus 8 (3):149–154. doi:10.2450/2010.0149-09PubMedCentralPubMed

23.

Steiner T, Freiberger A, Griebe M, Husing J, Ivandic B, Kollmar R, Pfefferkorn T, Wartenberg KE, Weimar C, Hennerici M, Poli S (2011) International normalised ratio normalisation in patients with coumarin-related intracranial haemorrhages—the INCH trial: a randomised controlled multicentre trial to compare safety and preliminary efficacy of fresh frozen plasma and prothrombin complex—study design and protocol. Int J Stroke 6 (3):271–277. doi:10.1111/j.1747-4949.2010.00560.xCrossRefPubMed

24.

Taggar JS, Lip GY (2008) Anticoagulation in atrial fibrillation: the trials and tribulations of keeping within therapeutic range. Curr Med Res Opin 24 (5):1455–1458. doi:10.1185/030079908X301875CrossRefPubMed

25.

Veltkamp R, Hacke W (2011) [New oral anticoagulants in atrial fibrillation]. Nervenarzt 82 (2):180, 182-184, 186-189. doi:10.1007/s00115-010-3114-5CrossRefPubMed

26.

Diener H-C, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, Xavier D, Di Pasquale G, Yusuf S, group R-Ls (2010) Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 9 (12):1157–1163. doi:10.1016/S1474-4422(10)70274-XCrossRefPubMed

27.

Douxfils J, Buckinx F, Mullier F, Minet V, Rabenda V, Reginster JY, Hainaut P, Bruyere O, Dogne JM (2014) Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 3 (3):e000515. doi:10.1161/JAHA.113.000515PubMedCentralCrossRefPubMed

28.

FDA (2014) FDA Drug Safety Communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin.

29.

Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KAA, Califf RM, Investigators RA (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England journal of medicine 365 (10):883–891. doi:10.1056/NEJMoa1009638CrossRefPubMed

30.

Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener H-C, Donnan GA, Halperin JL, Mahaffey KW, Mas J-L, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, Singer DE, Wong L, Califf RM, Fox KAA, Hacke W, Investigators RASC (2012) Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 11 (4):315–322.CrossRefPubMed

31.

Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L (2011) Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. doi:10.1056/NEJMoa1107039

32.

Connolly SJ, Eikelboom J, Joyner C, Diener H-C, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim K-H, Lewis BS, Van Mieghem W, Lip GYH, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S, Investigators ASCa (2011) Apixaban in patients with atrial fibrillation. The New England journal of medicine 364 (9):806–817.CrossRefPubMed

33.

Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L, Alings M, Goto S, Lewis BS, Rosenqvist M, Hanna M, Mohan P, Alexander JH, Diener HC (2012) Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol. doi:S1474-4422(12)70092-3 [pii] 10.1016/S1474-4422(12)70092-3

34.

Diener H-C, Eikelboom J, Connolly SJ, Joyner CD, Hart RG, Lip GY, O'Donnell M, Hohnloser SH, Hankey GJ, Shestakovska O, Yusuf S, investigators ftAsca (2012) Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol 11 (3):225–231.CrossRefPubMed

35.

Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM, Investigators EA-T (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369 (22):2093–2104. doi:10.1056/NEJMoa1310907CrossRefPubMed

36.

CRDAC (2014) FDA Draft Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee.

37.

Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O’Donnell MJ, Sacco RL, Connolly SJ, Cryptogenic Stroke EIWG (2014) Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 13 (4):429–438. doi:10.1016/S1474-4422(13)70310-7CrossRefPubMed

38.

Cadiss trial investigators, Markus HS, Hayter E, Levi C, Feldman A, Venables G, Norris J (2015) Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial. Lancet Neurol 14 (4):361–367. doi:10.1016/S1474-4422(15)70018-9CrossRef

39.

Gensicke H, Ahlhelm F, Jung S, von Hessling A, Traenka C, Goeggel Simonetti B, Peters N, Bonati LH, Fischer U, Broeg-Morvay A, Seiffge DJ, Gralla J, Stippich C, Baumgartner RW, Lyrer PA, Arnold M, Engelter ST (2015) New ischaemic brain lesions in cervical artery dissection stratified to antiplatelets or anticoagulants. Eur J Neurol 22 (5):859–865, e861. doi:10.1111/ene.12682CrossRefPubMed

40.

Ringelstein E (2012) Spontane Dissektionen der extrakraniellen und intrakraniellen hirnversorgenden Arterien. Leitlinien DGN

41.

Khan AR, Bin Abdulhak AA, Sheikh MA, Khan S, Erwin PJ, Tleyjeh I, Khuder S, Eltahawy EA (2013) Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke: a systematic review and meta-analysis. JACC Cardiovasc Interv 6 (12):1316–1323. doi:10.1016/j.jcin.2013.08.001CrossRefPubMed

42.

Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y, Lobmeyer MT, Maas H, Voigt JU, Simoons ML, Van de Werf F, Investigators R-A (2013) Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 369 (13):1206–1214. doi:10.1056/NEJMoa1300615CrossRefPubMed

43.

Zylla MM, Pohlmeier M, Hess A, Mereles D, Kieser M, Bruckner T, Scholz E, Zitron E, Schweizer PA, Katus HA, Thomas D (2015) Prevalence of intracardiac thrombi under phenprocoumon, direct oral anticoagulants (dabigatran and rivaroxaban), and bridging therapy in patients with atrial fibrillation and flutter. Am J Cardiol 115 (5):635–640. doi:10.1016/j.amjcard.2014.12.016CrossRefPubMed

44.

Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P, European Heart Rhythm A (2013) European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 15 (5):625–651. doi:10.1093/europace/eut083CrossRefPubMed

45.

Veltkamp R, Heuschmann PU, Haas K, Horstmann S, Rizos T, Purrucker J (2015) Register für akute Schlaganfälle unter neuen oralen Antikoagulanzien (RASUNOAprime). Dtsch Med Wochenschr 140 Suppl 1:S10. doi:10.1055/s-0041-101311PubMed

46.

Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, Garcia DA, Jacobson A, Jaffer AK, Kong DF, Schulman S, Turpie AG, Hasselblad V, Ortel TL, Investigators B (2015) Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med 373 (9):823–833. doi:10.1056/NEJMoa1501035CrossRefPubMed

47.

Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, van Eickels M, Turpie AG, Investigators X (2015) XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. doi:10.1093/eurheartj/ehv466

48.

Hernandez I, Baik SH, Pinera A, Zhang Y (2015) Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med 175 (1):18–24. doi:10.1001/jamainternmed.2014.5398CrossRefPubMed

49.

Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M (2015) Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis. Circulation 132 (3):194–204. doi:10.1161/CIRCULATIONAHA.114.013267CrossRefPubMed

50.

Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, Shah ND (2015) Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ 350:h1857. doi:10.1136/bmj.h1857PubMedCentralCrossRefPubMed

51.

Sardar P, Chatterjee S, Wu WC, Lichstein E, Ghosh J, Aikat S, Mukherjee D (2013) New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisons. PLoS One 8 (10):e77694. doi:10.1371/journal.pone.0077694PubMedCentralCrossRefPubMed

52.

Bode WD, Patel N, Gehi AK (2015) Left atrial appendage occlusion for prevention of stroke in nonvalvular atrial fibrillation: a meta-analysis. J Interv Card Electrophysiol 43 (1):79–89. doi:10.1007/s10840-015-9988-1CrossRefPubMed

53.

Horstmann S, Zugck C, Krumsdorf U, Rizos T, Rauch G, Geis N, Hardt S, Veltkamp R (2014) Left atrial appendage occlusion in atrial fibrillation after intracranial hemorrhage. Neurology 82 (2):135–138. doi:10.1212/WNL.0000000000000022PubMedCentralCrossRefPubMed

54.

Kuramatsu JB, Gerner ST, Schellinger PD, Glahn J, Endres M, Sobesky J, Flechsenhar J, Neugebauer H, Juttler E, Grau A, Palm F, Rother J, Michels P, Hamann GF, Huwel J, Hagemann G, Barber B, Terborg C, Trostdorf F, Bazner H, Roth A, Wohrle J, Keller M, Schwarz M, Reimann G, Volkmann J, Mullges W, Kraft P, Classen J, Hobohm C, Horn M, Milewski A, Reichmann H, Schneider H, Schimmel E, Fink GR, Dohmen C, Stetefeld H, Witte O, Gunther A, Neumann-Haefelin T, Racs AE, Nueckel M, Erbguth F, Kloska SP, Dorfler A, Kohrmann M, Schwab S, Huttner HB (2015) Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 313 (8):824–836. doi:10.1001/jama.2015.0846CrossRefPubMed

55.

Nielsen PB, Larsen TB, Skjoth F, Gorst-Rasmussen A, Rasmussen LH, Lip GY (2015) Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding: A Nationwide Cohort Study. Circulation 132 (6):517–525. doi:10.1161/CIRCULATIONAHA.115.015735CrossRefPubMed

56.

Pollack CV, Jr., Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI (2015) Idarucizumab for Dabigatran Reversal. N Engl J Med. doi:10.1056/NEJMoa1502000

57.

Gomez-Outes A, Suarez-Gea ML, Lecumberri R, Terleira-Fernandez AI, Vargas-Castrillon E (2014) Specific antidotes in development for reversal of novel anticoagulants: a review. Recent Pat Cardiovasc Drug Discov 9 (1):2–10CrossRefPubMed

Titel: Schlaganfall
Sekundärprophylaxe mit oralen Antikoagulanzien
verfasst von: Dr. med. Jan C. Purrucker
Prof. Dr. med. Peter A. Ringleb
PD Dr. med. Timolaos Rizos
Publikationsdatum: 03.12.2015
Verlag: Springer Medizin
Erschienen in: DNP – Die Neurologie & Psychiatrie / Ausgabe 12/2015
Print ISSN: 2731-8168
Elektronische ISSN: 2731-8176
DOI: https://doi.org/10.1007/s15202-015-1086-9

Neu in den Fachgebieten Neurologie und Psychiatrie

18.04.2024 | Arterielle Hypertonie | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Sekundärprophylaxe mit oralen Antikoagulanzien

Zusammenfassung

Neu in den Fachgebieten Neurologie und Psychiatrie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Delir kann Demenz begünstigen

Manche Gestagene können das Risiko für Meningeome erhöhen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2015

Kniffe für die Abrechnung der psychiatrischen Untersuchung

Aknemittel bremst MS nach erstem Schub

Stimmt Ihre Work-Life-Balance? — Machen Sie den Test!

THS auch bei psychiatrischen Erkrankungen einsetzen?

Folsäure zur Primärprävention des Schlaganfalls möglicherweise sinnvoll

Keine Schübe mehr? Therapiestopp ist dann keine gute Idee

Neu in den Fachgebieten Neurologie und Psychiatrie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Delir kann Demenz begünstigen

Manche Gestagene können das Risiko für Meningeome erhöhen